UNSPSC 51173009: Betamethasone/lidocaine/phenylephrine

Definition: This classification is for a combination analgesic and antiinflammatory therapy. The first component, BETAMETHASONE, has US FDA Unique Ingredient Identifier of 9842X06Q6M. The second component, LIDOCAINE, has US FDA Unique Ingredient Identifier of 98PI200987. The third component, PHENYLEPHRINE, has US FDA Unique Ingredient Identifier of 1WS297W6MV.

UNSPSC 51173009 Betamethasone/lidocaine/phenylephrine, a Commodity code, shows minimal recent state and local procurement activity directly tied to this specific pharmaceutical combination. The most recent opportunities block contains no active solicitations for this compound. Instead, the recent activity under related pharmaceutical and medical supply codes reflects state and local governments' procurement of broader emergency medical services (EMS) pharmaceuticals, supplies, and OTC products through competitive bidding, cooperative purchasing vehicles, and informal quotes, with issuing bodies spanning county health departments, fire departments, forensic laboratories, and state multistate cooperative purchasing alliances.

The geographic spread of pharmaceutical and medical supply procurement activity appears concentrated in Florida (Seminole County, Pinellas County, Collier County), Arizona (City of Tucson), and multistate cooperative frameworks administered through Minnesota. Representative recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 systems annually, due July 26, 2023); the City of Tucson Fire Department's RFP for BLS and ALS pharmaceuticals, supplies, and vending machine software (due June 24, 2026, with federal compliance obligations including prevailing wage, DBE participation, and Section 3 labor requirements); Pinellas County, Florida's Invitation to Quote for certified reference materials and drug standards for forensic analysis (due April 23, 2026, with SBE preference); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities (due March 26, 2026). No recent solicitation explicitly targets betamethasone/lidocaine/phenylephrine combinations; vendors pursuing this code should monitor pharmaceutical cooperative purchasing vehicles and state health department acquisitions for indirect demand signals.